Real World Evidence Solutions Market - Global Forecast to 2030
商品番号 : SMB-4518
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 377 |
| 図表数 | 500 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、リアルワールドエビデンス（RWE）ソリューション市場を、コンポーネント、用途、収益モデル、導入形態、エンドユーザー、地域の観点から分析しています。また、市場の成長要因（成長促進要因、阻害要因、機会、課題）も分析しています。ステークホルダーにとっての市場機会と課題を評価し、市場リーダーの競争環境を詳細に分析しています。さらに、ミクロ市場についても、その成長傾向、見通し、そしてリアルワールドエビデンス（RWE）ソリューション市場全体への貢献度について調査しています。さらに、5つの地域における市場セグメントの収益予測も行っています。
世界のリアルワールドエビデンス（RWE）ソリューション市場は、2025年の54億2,000万米ドルから2030年には108億3,000万米ドルに達し、予測期間中に年平均成長率（CAGR）14.8%で成長すると予測されています。市場の成長は、価値に基づくケアへの移行と慢性疾患の罹患率の増加によって促進されています。リアルワールドエビデンス（RWE）は、医薬品開発プロセスにおけるコストと時間の両方を削減する可能性を秘めています。そのため、製薬企業および医療機器企業におけるRWEソリューションの導入が拡大しています。
The global real world evidence solutions market is projected to reach USD 10.83 billion by 2030 from USD 5.42 billion in 2025, at a CAGR of 14.8% during the forecast period. The market’s growth is fueled by the transition to value-based care and the increasing incidence of chronic diseases. Real world evidence (RWE) can potentially reduce both costs and time in the drug development process. This has resulted in the growing adoption of RWE solutions across pharmaceutical & medical device companies.
“By component, the data sets segment is expected to grow at the highest CAGR during the forecast period.”
Based on component, the real world evidence solution market is segmented into services, data sets, and integrated data sets. The data sets segment is projected to grow at the highest CAGR during the forecast period. With the growing digitization of healthcare and increasing acceptance of real world data by regulators such as the FDA and EMA; the demand for high-quality, curated datasets, such as EHRs, claims, and registry data, has surged. These datasets power analytics, AI models, and health economics studies, making them critical assets for pharma, biotech, and healthcare companies. Additionally, their recurring revenue potential through licensing further drives their dominance in the RWE landscape.
“By application, the post-market surveillance segment is expected to register the highest CAGR during the forecast period.”
By application, the real world evidence solutions market is segmented into drug development & approvals, medical device development & approvals, post-market surveillance, market access & reimbursement decision-making, clinical & regulatory decision-making, and other applications. The post-market surveillance segment is expected to register the highest CAGR during the forecast period. The increasing regulatory focus on long-term safety and the efficacy of drugs & medical devices after market approval drives the high growth rate of this segment. Regulatory agencies such as the US FDA, the EMA, and the PMDA in Japan have emphasized monitoring real-world outcomes to identify adverse events, track product performance, and support risk management plans.
“By end user, the pharmaceutical & biotechnology companies segment is projected to grow at the highest CAGR during the forecast period.”
The RWE solutions market is segmented by end users into pharmaceutical & biotechnology companies, MedTech companies, healthcare payers, healthcare providers, and other end users. The pharmaceutical & biotechnological companies segment is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include adopting RWE solutions to decrease the costs & time for drug development, as RWE data provides clinical insights on the development of new drugs & medical devices. The high growth in the pharmaceutical industry is also an additional factor, fueling the adoption of real world solutions.
“The Asia Pacific region is projected to register the highest CAGR during the forecast period.”
The market is segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The RWE solutions market in the Asia Pacific region is projected to register the highest CAGR during the forecast period. The high growth rate of this region is attributed to the rising initiatives towards adopting RWE by pharmaceutical & medical device companies. This rapid expansion is driven by the high volume of clinical trials undertaken by emerging economies such as China, India, Japan, and South Korea, along with evolving regulatory frameworks that are beginning to accept RWE for drug approvals and post-market surveillance.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: C-level (35%), Director-level (45%), and Others (20%)
- By Region: North America (55%), Europe (20%), the Asia Pacific (15%), Latin America (5%), and the Middle East & Africa (5%)
List of Companies Profiled in the Report
o IQVIA Inc. (US)
o Merative (US)
o Optum Inc. (US)
o ICON Plc (Ireland)
o Syneos Health (US)
o Parexel International Corporation (US)
o Tata Consultancy Services (India)
o Oracle (US)
o Elevance Health (US)
o SAS Institute Inc. (US)
o Aetion Inc. (US)
o Trinetx LLC (US)
o Trinity (US)
o Cognizant Technology Solutions Corporation (US)
o Cegedim Health Data (France)
o Verantos (US)
o Medspace Holdings Inc. (US)
o FLATIRON HEALTH (US)
o Fortrea (US)
o Medidata (US) (subsidiary of Dassault Systèmes)
o HealthVerity, Inc. (US)
o Quantzig (US)
o OPEN Health (UK)
o Tempus (US)
o Certara (US)
Research Coverage
This report studies the real world evidence solutions market based on component, application, revenue model, deployment mode, end user, and region. The report also analyzes market growth factors (drivers, restraints, opportunities, and challenges). It evaluates the market’s opportunities and challenges for stakeholders and details the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total real world evidence solutions market. The report forecasts the revenue of the market segments in five regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (rising geriatric population and rise in incidences of chronic diseases, shift from volume-based care to value-based care, potential of RWE in reducing drug development costs and expediting drug development process, increased R&D spending for development of new pharmaceutical products and medical devices, and support from regulatory bodies for use of RWE solutions), restraints (reluctance of medical practitioners and researchers to rely on real-world studies), opportunities (increase focus on end-to-end RWE services, and growth opportunities in emerging markets), and challenges (scarcity of skilled personnel, and the lack of universally accepted methodology principles and data processing infrastructure).
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the real world evidence solutions market.
- Market Development: Comprehensive information on the lucrative emerging markets, by component, application, revenue model, deployment mode, end user, and region.
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the real world evidence solutions market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation matrix, and capabilities of leading players in the global real world evidence solutions market.
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 STUDY SCOPE 36
1.3.1 MARKET SEGMENTATION 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.4 YEARS CONSIDERED 38
1.5 CURRENCY CONSIDERED 38
1.6 STAKEHOLDERS 38
1.7 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 44
2.1.2.2 Key industry insights 45
2.2 RESEARCH METHODOLOGY DESIGN 46
2.3 MARKET SIZE ESTIMATION 47
2.3.1 BOTTOM-UP APPROACH 48
2.3.2 TOP-DOWN APPROACH 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.5 RESEARCH ASSUMPTIONS 52
2.6 RISK ASSESSMENT 52
2.7 LIMITATIONS 53
2.7.1 SCOPE-RELATED LIMITATIONS 53
2.7.2 METHODOLOGY-RELATED LIMITATIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 60
4.1 REAL WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW 60
4.2 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER AND COUNTRY 61
4.3 REAL WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
4.4 REGIONAL MIX: REAL WORLD EVIDENCE SOLUTIONS MARKET, 2025−2030 62
4.5 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES, 2025 VS. 2030 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 66
5.2.1.1 Rising geriatric population and subsequent increase in prevalence of chronic diseases 66
5.2.1.2 Shift from volume-based care to value-based care 66
5.2.1.3 Potential of real world evidence in reducing drug development costs and expediting drug development process 67
5.2.1.4 Increased R&D spending for development of new pharmaceutical products and medical devices 68
5.2.1.5 Support from regulatory bodies for use of real world evidence solutions 69
5.2.2 RESTRAINTS 69
5.2.2.1 Reluctance of medical practitioners and researchers to rely on real world studies 69
5.2.2.2 Data quality and standardization issues 70
5.2.3 OPPORTUNITIES 70
5.2.3.1 Growth opportunities in emerging markets 70
5.2.3.2 Increased focus on end-to-end RWE services 71
5.2.3.3 Increased focus on personalized and precision medicine 71
5.2.3.4 Market access, health technology assessment (HTA), and reimbursement 72
5.2.4 CHALLENGES 73
5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure 73
5.2.4.2 Shortage of skilled professionals 73
5.3 INDUSTRY TRENDS 74
5.3.1 EMERGING ROLE OF WEARABLE DEVICES 74
5.3.2 SOCIAL MEDIA-SOURCED RWE 74
5.3.3 RISING USE OF RWD AND RWE ACROSS PHARMACEUTICAL INDUSTRY 75
5.3.4 RWE ANALYTICS APPROACH: INTERNAL VS. OUTSOURCED 76
5.3.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE INTO RWD MANAGEMENT 77
5.4 REAL WORLD DATA SOURCES 77
5.5 ECOSYSTEM ANALYSIS 79
5.6 VALUE CHAIN ANALYSIS 82
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 84
5.8 PORTER’S FIVE FORCES ANALYSIS 85
5.8.1 THREAT FROM NEW ENTRANTS 86
5.8.2 BARGAINING POWER OF SUPPLIERS 86
5.8.3 BARGAINING POWER OF BUYERS 86
5.8.4 THREAT FROM SUBSTITUTES 86
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.9 PRICING ANALYSIS 87
5.9.1 INDICATIVE PRICING FOR REAL WORLD EVIDENCE SOLUTIONS,
BY COMPONENT 87
5.9.2 INDICATIVE PRICING OF REAL WORLD EVIDENCE SOLUTIONS, BY REGION 88
5.10 TECHNOLOGY ANALYSIS 89
5.10.1 KEY TECHNOLOGIES 89
5.10.1.1 Use of AI and ML 89
5.10.1.2 Blockchain technology 90
5.10.2 ADJACENT TECHNOLOGIES 90
5.10.2.1 Predictive analytics 90
5.10.2.2 Visualization dashboard software 90
5.10.3 COMPLEMENTARY TECHNOLOGIES 91
5.10.3.1 Electronic health records (EHRs) 91
5.10.3.2 Clinical trial management system 91
5.11 TARIFF AND REGULATORY LANDSCAPE 92
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
5.11.2 REGULATORY ANALYSIS 93
5.11.2.1 North America 93
5.11.2.1.1 US 93
5.11.2.1.1.1 Use cases 94
5.11.2.1.2 Canada 94
5.11.2.2 Europe 95
5.11.2.3 Asia Pacific 95
5.11.2.3.1 China 95
5.11.2.3.2 Japan 96
5.11.2.3.3 India 96
5.11.2.4 Middle East & Africa 97
5.11.2.5 Latin America 97
5.12 PATENT ANALYSIS 97
5.12.1 PATENT PUBLICATION TRENDS FOR REAL WORLD EVIDENCE SOLUTIONS MARKET 97
5.12.2 JURISDICTION AND TOP APPLICANT ANALYSIS 98
5.13 KEY CONFERENCES & EVENTS 101
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 102
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
5.14.2 BUYING CRITERIA 103
5.15 CASE STUDY ANALYSIS 104
5.15.1 DESIGNING AND BUILDING RWE DASHBOARDS AND LEVERAGING EHR AND CLAIMS DATA 104
5.15.2 INTEGRATING SPECIALTY PHARMACY AND PATIENT HUB DATA WITH RWD DATA TO INVESTIGATE INTO NON-ADHERENCE FACTORS 104
5.15.3 SIMPLIFYING DATA ANALYTICS WITH RWE PLATFORM 105
5.16 END USER ANALYSIS 105
5.16.1 UNMET NEEDS 105
5.16.2 END USER EXPECTATIONS 106
5.17 REAL WORLD EVIDENCE SOLUTIONS MARKET: BUSINESS MODELS 107
5.17.1 PLATFORM-AS-A-SERVICE (PAAS) MODEL 107
5.17.2 DATA PROVIDER MODEL 107
5.17.3 CONSULTING AND SERVICES MODEL 107
5.17.4 COLLABORATIVE RESEARCH MODEL 107
5.18 INVESTMENT & FUNDING SCENARIO 108
5.19 IMPACT OF AI/GENERATIVE AI ON REAL WORLD EVIDENCE SOLUTIONS MARKET 108
5.19.1 TOP USE CASES & MARKET POTENTIAL 108
5.19.1.1 Key use cases 109
5.19.2 IMPLEMENTATION OF AI/GENERATIVE AI: CASE STUDIES 110
5.19.2.1 AI-powered RWE transformed patient targeting and treatment initiation 110
5.19.3 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT MARKET ECOSYSTEM 111
5.19.3.1 Electronic health record (EHR) market 111
5.19.3.2 Real world data (RWD) market 112
5.19.4 USER READINESS AND IMPACT ASSESSMENT 112
5.20 US TARIFF 2025 113
5.20.1 INTRODUCTION 113
5.20.2 KEY TARIFF RATES 114
5.20.3 PRICE IMPACT ANALYSIS 114
5.20.4 IMPACT ON COUNTRY/REGION 115
5.20.4.1 US 115
5.20.4.2 Europe 116
5.20.4.3 Asia Pacific 116
5.20.5 IMPACT ON END-USE INDUSTRIES 117
6 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT 118
6.1 INTRODUCTION 119
6.2 SERVICES 119
6.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND 119
6.3 DATA SETS 120
6.3.1 DISPARATE DATA SETS 121
6.3.1.1 Clinical settings data sets 122
6.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth 122
6.3.1.2 Claims data sets 123
6.3.1.2.1 Growing need to understand economic benefits of drug reimbursement by payers to drive growth 123
6.3.1.3 Pharmacy data sets 124
6.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth 124
6.3.1.4 Patient-powered data sets 125
6.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth 125
6.3.1.5 Registry-based data sets 126
6.3.1.5.1 Increasing number of disease registries to drive demand for registry-based data sets in evidence generation 126
6.3.1.6 Others 127
6.3.1.6.1 Increasing number of genomics registries to drive demand for RWE evidence solutions 127
6.3.2 INTEGRATED DATA SETS 128
6.3.2.1 Increasing demand for integrated data from multiple sources to drive growth 128
7 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION 129
7.1 INTRODUCTION 130
7.2 DRUG DEVELOPMENT & APPROVALS 130
7.2.1 ONCOLOGY 131
7.2.1.1 Growing number of clinical trials focused on cancer treatment to drive demand 131
7.2.2 CARDIOVASCULAR DISEASES 132
7.2.2.1 High prevalence of cardiovascular diseases to support market growth 132
7.2.3 NEUROLOGY 133
7.2.3.1 Rapidly aging global population and subsequent increase in prevalence of neurological disorders to drive growth 133
7.2.4 IMMUNOLOGY 134
7.2.4.1 Increasing focus on developing innovative products to drive growth 134
7.2.5 RARE DISEASES 135
7.2.5.1 Need for harnessing RWE to advance therapies for rare diseases to boost market 135
7.2.6 OTHER THERAPEUTIC AREAS 136
7.3 MEDICAL DEVICE DEVELOPMENT & APPROVALS 137
7.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND 137
7.4 POST-MARKET SURVEILLANCE 138
7.4.1 EXTENSIVE USE OF RWE SOLUTIONS IN POST-MARKET SURVEILLANCE TO BOOST MARKET 138
7.5 MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING 139
7.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TO FAVOR MARKET GROWTH 139
7.6 CLINICAL & REGULATORY DECISION-MAKING 140
7.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS TO DRIVE USE OF RWE SOLUTIONS 140
7.7 OTHER APPLICATIONS 141
8 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL 143
8.1 INTRODUCTION 144
8.2 PAY-PER-USAGE (VALUE-BASED PRICING) 144
8.2.1 RISING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE SOLUTIONS TO BOOST MARKET 144
8.3 SUBSCRIPTION 145
8.3.1 RISING PREFERENCE FOR FLEXIBILITY AND SCALABILITY TO SUPPORT MARKET GROWTH 145
8.4 LICENSE 146
8.4.1 FOCUS ON ENABLING END-TO-END RWE DELIVERY THROUGH PLATFORM LICENSING TO DRIVE MARKET 146
9 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE 148
9.1 INTRODUCTION 149
9.2 ON-PREMISES 149
9.2.1 NEED FOR ENHANCED DATA CONTROL BENEFITS TO BOOST DEMAND 149
9.3 CLOUD-BASED 150
9.3.1 INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH 150
9.4 HYBRID 151
9.4.1 EMPHASIS ON INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH 151
10 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER 152
10.1 INTRODUCTION 153
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 153
10.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH 153
10.3 MEDTECH COMPANIES 154
10.3.1 NEED FOR ACCELERATING MEDTECH MARKET ACCESS VIA REAL WORLD EVIDENCE SOLUTIONS TO BOOST GROWTH 154
10.4 HEALTHCARE PAYERS 155
10.4.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND 155
10.5 PUBLIC PAYERS 156
10.5.1 FOCUS ON ENHANCING PUBLIC PAYER DECISION-MAKING WITH RWE SOLUTIONS TO BOOST MARKET 156
10.6 PRIVATE PAYERS 157
10.6.1 NEED FOR LEVERAGING PRIVATE PAYERS FOR SUSTAINABLE RWE SOLUTIONS TO SPUR DEMAND 157
10.7 HEALTHCARE PROVIDERS 158
10.7.1 GROWING FOCUS ON IMPROVING PROFITABILITY TO SUPPORT MARKET GROWTH 158
10.7.2 HOSPITALS 159
10.7.3 CLINICS & OTHER OUTPATIENT SETTINGS 160
10.7.4 OTHER HEALTHCARE PROVIDERS 161
10.8 OTHER END USERS 161
11 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION 163
11.1 INTRODUCTION 164
11.2 NORTH AMERICA 164
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 164
11.2.2 US 169
11.2.2.1 US to account for significant share of North American market 169
11.2.3 CANADA 174
11.2.3.1 Increase in pharma hub growth in Canada to drive market 174
11.3 EUROPE 178
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 178
11.3.2 GERMANY 183
11.3.2.1 High pharmaceutical R&D spending in Germany to boost market growth 183
11.3.3 UK 187
11.3.3.1 Growing adoption of HTA to support market growth 187
11.3.4 FRANCE 191
11.3.4.1 Need for extensive and diversified database to drive market growth 191
11.3.5 ITALY 195
11.3.5.1 High demand for RWE due to widespread use of pay-for-outcomes to drive market 195
11.3.6 SPAIN 199
11.3.6.1 Rising R&D expenditure to propel market growth 199
11.3.7 REST OF EUROPE 204
11.4 ASIA PACIFIC 209
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 209
11.4.2 JAPAN 214
11.4.2.1 Stringent regulatory scenario in Japan to restrain market growth 214
11.4.3 CHINA 218
11.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market 218
11.4.4 INDIA 223
11.4.4.1 Growing adoption of outcome-based research to drive market 223
11.4.5 AUSTRALIA 227
11.4.5.1 Policy reforms and strong regulations to support market growth 227
11.4.6 SOUTH KOREA 231
11.4.6.1 Increased focus on pharma R&D to boost market growth 231
11.4.7 REST OF ASIA PACIFIC 235
11.5 LATIN AMERICA 240
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 240
11.5.2 BRAZIL 244
11.5.2.1 Evolving regulatory frameworks that facilitate clinical research to drive market 244
11.5.3 MEXICO 248
11.5.3.1 Increased funding and investments in pharma R&D to favor growth 248
11.5.4 REST OF LATIN AMERICA 252
11.6 MIDDLE EAST & AFRICA 256
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 257
11.6.2 GCC COUNTRIES 261
11.6.2.1 Growing availability of healthcare funding to offer opportunities for market growth 261
11.6.2.2 Saudi Arabia 266
11.6.2.2.1 Digital health reform and regulatory innovation to offer opportunities for market growth 266
11.6.2.3 UAE 270
11.6.2.3.1 Need for driving data-driven healthcare transformation to boost market 270
11.6.2.4 Rest of GCC 274
11.6.3 SOUTH AFRICA 278
11.6.3.1 Emphasis on supporting healthcare infrastructure to drive market growth 278
11.6.4 REST OF MIDDLE EAST & AFRICA 282
12 COMPETITIVE LANDSCAPE 286
12.1 INTRODUCTION 286
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 286
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 286
12.3 REVENUE SHARE ANALYSIS 289
12.4 MARKET SHARE ANALYSIS 289
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 292
12.5.1 STARS 292
12.5.2 EMERGING LEADERS 292
12.5.3 PERVASIVE PLAYERS 292
12.5.4 PARTICIPANTS 292
12.5.5 COMPANY FOOTPRINT 294
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 299
12.6.1 PROGRESSIVE COMPANIES 299
12.6.2 RESPONSIVE COMPANIES 299
12.6.3 DYNAMIC COMPANIES 299
12.6.4 STARTING BLOCKS 299
12.6.5 COMPETITIVE BENCHMARKING 301
12.7 BRAND/PRODUCT COMPARISON 302
12.8 VALUATION AND FINANCIAL METRICS 302
12.9 COMPETITIVE SCENARIO 303
12.9.1 PRODUCT LAUNCHES/ENHANCEMENTS 303
12.9.2 DEALS 304
12.9.3 OTHER DEVELOPMENTS 305
13 COMPANY PROFILES 306
13.1 KEY PLAYERS 306
13.1.1 IQVIA 306
13.1.1.1 Business overview 306
13.1.1.2 Products offered 307
13.1.1.3 Recent developments 308
13.1.1.3.1 Deals 308
13.1.1.4 MnM view 309
13.1.1.4.1 Key strengths/Right to win 309
13.1.1.4.2 Strategic choices 309
13.1.1.4.3 Weaknesses and competitive threats 309
13.1.2 MERATIVE 310
13.1.2.1 Business overview 310
13.1.2.2 Products offered 310
13.1.2.3 Recent developments 311
13.1.2.3.1 Deals 311
13.1.2.3.2 Other developments 311
13.1.2.4 MnM view 312
13.1.2.4.1 Key strengths/Right to win 312
13.1.2.4.2 Strategic choices 312
13.1.2.4.3 Weaknesses and competitive threats 312
13.1.3 OPTUM, INC. 313
13.1.3.1 Business overview 313
13.1.3.2 Products offered 314
13.1.3.3 Recent developments 315
13.1.3.3.1 Product launches/developments 315
13.1.3.3.2 Deals 315
13.1.3.4 MnM view 316
13.1.3.4.1 Key strengths/Right to win 316
13.1.3.4.2 Strategic choices made 316
13.1.3.4.3 Weaknesses and competitive threats 316
13.1.4 ICON PLC 317
13.1.4.1 Business overview 317
13.1.4.2 Products offered 318
13.1.4.3 Recent developments 319
13.1.4.3.1 Product launches/developments 319
13.1.4.3.2 Deals 319
13.1.4.4 MnM view 320
13.1.4.4.1 Key strengths/Right to win 320
13.1.4.4.2 Strategic choices 320
13.1.4.4.3 Weaknesses and competitive threats 320
13.1.5 SYNEOS HEALTH 321
13.1.5.1 Business overview 321
13.1.5.2 Products offered 321
13.1.5.3 Recent developments 322
13.1.5.3.1 Deals 322
13.1.5.4 MnM view 323
13.1.5.4.1 Key strengths/Right to win 323
13.1.5.4.2 Strategic choices 323
13.1.5.4.3 Weaknesses and competitive threats 323
13.1.6 PAREXEL INTERNATIONAL (MA) CORPORATION 324
13.1.6.1 Business overview 324
13.1.6.2 Products offered 324
13.1.6.3 Recent developments 325
13.1.6.3.1 Product launches/developments 325
13.1.6.3.2 Deals 325
13.1.7 FLATIRON HEALTH 327
13.1.7.1 Business overview 327
13.1.7.2 Products offered 327
13.1.7.3 Recent developments 328
13.1.7.3.1 Product launches/developments 328
13.1.7.3.2 Deals 328
13.1.8 FORTREA 330
13.1.8.1 Business overview 330
13.1.8.2 Products offered 331
13.1.8.3 Recent developments 332
13.1.8.3.1 Product launches/developments 332
13.1.8.3.2 Deals 332
13.1.9 ORACLE 333
13.1.9.1 Business overview 333
13.1.9.2 Products offered 334
13.1.9.3 Recent developments 335
13.1.9.3.1 Product launches/developments 335
13.1.9.3.2 Deals 335
13.1.10 ELEVANCE HEALTH 337
13.1.10.1 Business overview 337
13.1.10.2 Products offered 338
13.1.11 SAS INSTITUTE INC. 339
13.1.11.1 Business overview 339
13.1.11.2 Products offered 339
13.1.11.3 Recent developments 340
13.1.11.3.1 Product launches/developments 340
13.1.12 AETION, INC. 341
13.1.12.1 Business overview 341
13.1.12.2 Products offered 341
13.1.12.3 Recent developments 342
13.1.12.3.1 Product launches/developments 342
13.1.12.3.2 Deals 342
13.1.13 TRINETX, LLC 344
13.1.13.1 Business overview 344
13.1.13.2 Products offered 344
13.1.13.3 Recent developments 345
13.1.13.3.1 Product launches/developments 345
13.1.13.3.2 Deals 345
13.1.14 TRINITY 347
13.1.14.1 Business overview 347
13.1.14.2 Products offered 347
13.1.14.3 Recent developments 348
13.1.14.3.1 Deals 348
13.1.15 MEDIDATA 349
13.1.15.1 Business overview 349
13.1.15.2 Products offered 349
13.1.15.3 Recent developments 350
13.1.15.3.1 Product launches/developments 350
13.1.15.3.2 Deals 350
13.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION 352
13.1.16.1 Business overview 352
13.1.16.2 Products offered 353
13.1.17 CEGEDIM HEALTH DATA 354
13.1.17.1 Business overview 354
13.1.17.2 Products offered 355
13.1.17.3 Recent developments 355
13.1.17.3.1 Product launches/developments 355
13.1.17.3.2 Deals 355
13.1.18 VERANTOS 356
13.1.18.1 Business overview 356
13.1.18.2 Products offered 356
13.1.18.3 Recent developments 357
13.1.18.3.1 Product launches/developments 357
13.1.18.3.2 Deals 358
13.1.19 MEDPACE 359
13.1.19.1 Business overview 359
13.1.19.2 Products offered 360
13.1.20 TATA CONSULTANCY SERVICES LIMITED 361
13.1.20.1 Business overview 361
13.1.20.2 Products offered 362
13.1.20.3 Recent developments 363
13.1.20.3.1 Deals 363
13.2 OTHER PLAYERS 364
13.2.1 HEALTHVERITY, INC. 364
13.2.2 OM1 364
13.2.3 OPEN HEALTH 365
13.2.4 TEMPUS 366
13.2.5 QUANTZIG 366
14 APPENDIX 367
14.1 DISCUSSION GUIDE 367
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 373
14.3 CUSTOMIZATION OPTIONS 375
14.4 RELATED REPORTS 375
14.5 AUTHOR DETAILS 376
LIST OF TABLES
TABLE 1 RISK ASSESSMENT ANALYSIS 52
TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS 65
TABLE 3 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 77
TABLE 4 REAL WORLD EVIDENCE SOLUTIONS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 81
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 6 INDICATIVE PRICING ANALYSIS OF REAL WORLD EVIDENCE SOLUTIONS,
BY DATA SET, 2024 (USD) 87
TABLE 7 INDICATIVE PRICE RANGE OF REAL WORLD EVIDENCE SOLUTIONS,
BY KEY REGION, 2024 (USD) 89
TABLE 8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 9 JURISDICTION ANALYSIS OF TOP APPLICANTS 98
TABLE 10 LIST OF PATENTS, 2017–2025 100
TABLE 11 DETAILED LIST OF CONFERENCES AND EVENTS 101
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS 103
TABLE 13 KEY BUYING CRITERIA FOR KEY APPLICATIONS 103
TABLE 14 UNMET NEEDS IN REAL WORLD EVIDENCE SOLUTIONS MARKET 105
TABLE 15 END USER EXPECTATIONS IN REAL WORLD EVIDENCE SOLUTIONS MARKET 106
TABLE 16 RECIPROCAL TARIFF RATES ADJUSTED BY US 114
TABLE 17 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 119
TABLE 18 REAL WORLD EVIDENCE SERVICES OFFERED BY KEY MARKET PLAYERS 120
TABLE 19 REAL WORLD EVIDENCE SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 20 REAL WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2023–2030 (USD MILLION) 121
TABLE 21 REAL WORLD EVIDENCE DATA SETS MARKET, BY REGION,
2023–2030 (USD MILLION) 121
TABLE 22 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 122
TABLE 23 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY REGION, 2023–2030 (USD MILLION) 122
TABLE 24 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS 123
TABLE 25 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 26 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS 124
TABLE 27 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY REGION, 2023–2030 (USD MILLION) 124
TABLE 28 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS,
BY REGION, 2023–2030 (USD MILLION) 125
TABLE 29 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS 125
TABLE 30 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 31 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 32 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER DATA SETS, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 33 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS 128
TABLE 34 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS,
BY REGION, 2023–2030 (USD MILLION) 128
TABLE 35 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 130
TABLE 36 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 131
TABLE 37 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 38 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY REGION,
2023–2030 (USD MILLION) 132
TABLE 39 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 133
TABLE 40 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION) 134
TABLE 41 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 42 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR RARE DISEASES, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 43 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 137
TABLE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 45 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY REGION, 2023–2030 (USD MILLION) 139
TABLE 46 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY REGION,
2023–2030 (USD MILLION) 140
TABLE 47 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY REGION, 2023–2030 (USD MILLION) 141
TABLE 48 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 142
TABLE 49 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 144
TABLE 50 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USAGE
(VALUE-BASED PRICING) MODEL, BY REGION, 2023–2030 (USD MILLION) 145
TABLE 51 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODEL,
BY REGION, 2023–2030 (USD MILLION) 146
TABLE 52 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR LICENSE MODEL, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 53 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE,
2023–2030 (USD MILLION) 149
TABLE 54 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISES MODE,
BY REGION, 2023–2030 (USD MILLION) 150
TABLE 55 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODE,
BY REGION, 2023–2030 (USD MILLION) 151
TABLE 56 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HYBRID MODE, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 57 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 153
TABLE 58 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 154
TABLE 59 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR MEDTECH COMPANIES,
BY REGION, 2023–2030 (USD MILLION) 155
TABLE 60 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS,
BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 61 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS,
BY REGION, 2023–2030 (USD MILLION) 156
TABLE 62 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PUBLIC PAYERS, BY REGION, 2023–2030 (USD MILLION) 157
TABLE 63 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR PRIVATE PAYERS, BY REGION, 2023–2030 (USD MILLION) 158
TABLE 64 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 65 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS,
BY REGION, 2023–2030 (USD MILLION) 159
TABLE 66 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 160
TABLE 67 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICS & OTHER OUTPATIENT SETTINGS, BY REGION, 2023–2030 (USD MILLION) 160
TABLE 68 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION) 161
TABLE 69 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS,
BY REGION, 2023–2030 (USD MILLION) 162
TABLE 70 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 164
TABLE 71 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 72 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 166
TABLE 73 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 74 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 75 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167
TABLE 76 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 167
TABLE 77 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 168
TABLE 78 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 168
TABLE 79 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 168
TABLE 80 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 169
TABLE 81 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 169
TABLE 82 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 170
TABLE 83 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 84 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 85 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 171
TABLE 86 US: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 87 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 172
TABLE 88 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE,
2023–2030 (USD MILLION) 172
TABLE 89 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 173
TABLE 90 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER,
2023–2030 (USD MILLION) 173
TABLE 91 US: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 173
TABLE 92 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 174
TABLE 93 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 94 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 95 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 175
TABLE 96 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 176
TABLE 97 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 176
TABLE 98 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 176
TABLE 99 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 177
TABLE 100 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 177
TABLE 101 CANADA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 177
TABLE 102 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 179
TABLE 103 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 179
TABLE 104 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 105 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 106 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 180
TABLE 107 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 108 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 181
TABLE 109 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 181
TABLE 110 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 182
TABLE 111 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 182
TABLE 112 EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 182
TABLE 113 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 183
TABLE 114 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY TYPE,
2023–2030 (USD MILLION) 184
TABLE 115 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 116 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 185
TABLE 117 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 118 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 186
TABLE 119 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 186
TABLE 120 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 186
TABLE 121 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 187
TABLE 122 GERMANY: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 187
TABLE 123 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 188
TABLE 124 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 125 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 126 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 189
TABLE 127 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 128 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 190
TABLE 129 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE,
2023–2030 (USD MILLION) 190
TABLE 130 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 131 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER,
2023–2030 (USD MILLION) 191
TABLE 132 UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 191
TABLE 133 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 192
TABLE 134 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 135 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 136 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 137 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 138 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 194
TABLE 139 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 194
TABLE 140 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 194
TABLE 141 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 195
TABLE 142 FRANCE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 195
TABLE 143 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 196
TABLE 144 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 145 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 146 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 197
TABLE 147 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 148 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 198
TABLE 149 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 198
TABLE 150 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 151 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 199
TABLE 152 ITALY: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 199
TABLE 153 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 200
TABLE 154 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 155 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 156 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 201
TABLE 157 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 158 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 202
TABLE 159 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 202
TABLE 160 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 161 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 203
TABLE 162 SPAIN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 203
TABLE 163 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 204
TABLE 164 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 165 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 166 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206
TABLE 167 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2023–2030 (USD MILLION) 206
TABLE 168 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 207
TABLE 169 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 207
TABLE 170 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 207
TABLE 171 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 208
TABLE 172 REST OF EUROPE: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 208
TABLE 173 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 210
TABLE 174 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 211
TABLE 175 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 176 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 177 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 212
TABLE 178 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 212
TABLE 179 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 213
TABLE 180 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 213
TABLE 181 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 213
TABLE 182 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 214
TABLE 183 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 214
TABLE 184 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 215
TABLE 185 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 186 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 187 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 216
TABLE 188 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 216
TABLE 189 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 217
TABLE 190 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 217
TABLE 191 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 217
TABLE 192 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 218
TABLE 193 JAPAN: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 218
TABLE 194 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 219
TABLE 195 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 196 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 197 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 198 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 221
TABLE 199 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 221
TABLE 200 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 221
TABLE 201 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 222
TABLE 202 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 222
TABLE 203 CHINA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 222
TABLE 204 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 223
TABLE 205 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 206 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 207 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 225
TABLE 208 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 225
TABLE 209 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 226
TABLE 210 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 226
TABLE 211 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 226
TABLE 212 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 227
TABLE 213 INDIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 227
TABLE 214 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 228
TABLE 215 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 216 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 217 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 229
TABLE 218 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 229
TABLE 219 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 230
TABLE 220 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 230
TABLE 221 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 230
TABLE 222 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 231
TABLE 223 AUSTRALIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 231
TABLE 224 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 232
TABLE 225 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 226 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 227 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233
TABLE 228 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 233
TABLE 229 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 234
TABLE 230 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 234
TABLE 231 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 234
TABLE 232 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 235
TABLE 233 SOUTH KOREA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 235
TABLE 234 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 236
TABLE 235 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR
DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 236
TABLE 236 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 236
TABLE 237 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 237
TABLE 238 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 237
TABLE 239 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 238
TABLE 240 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 238
TABLE 241 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 238
TABLE 242 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 239
TABLE 243 REST OF ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 239
TABLE 244 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION,
2023–2030 (USD MILLION) 240
TABLE 245 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 241
TABLE 246 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 247 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 248 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242
TABLE 249 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 242
TABLE 250 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 243
TABLE 251 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 243
TABLE 252 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 243
TABLE 253 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 244
TABLE 254 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 244
TABLE 255 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 245
TABLE 256 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 257 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 258 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 246
TABLE 259 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 246
TABLE 260 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 247
TABLE 261 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 247
TABLE 262 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 263 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 248
TABLE 264 BRAZIL: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 248
TABLE 265 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 249
TABLE 266 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 267 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 268 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 250
TABLE 269 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250
TABLE 270 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 251
TABLE 271 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 251
TABLE 272 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 251
TABLE 273 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 252
TABLE 274 MEXICO: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 252
TABLE 275 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 252
TABLE 276 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR
DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 277 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 278 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 254
TABLE 279 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 254
TABLE 280 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 255
TABLE 281 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 255
TABLE 282 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 255
TABLE 283 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 256
TABLE 284 REST OF LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 256
TABLE 285 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REGION, 2023–2030 (USD MILLION) 257
TABLE 286 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 257
TABLE 287 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR
DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 288 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 289 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 259
TABLE 290 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 259
TABLE 291 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 260
TABLE 292 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 260
TABLE 293 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 260
TABLE 294 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 261
TABLE 295 MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 261
TABLE 296 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 262
TABLE 297 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 262
TABLE 298 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 299 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 300 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263
TABLE 301 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 264
TABLE 302 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 264
TABLE 303 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 264
TABLE 304 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 265
TABLE 305 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 265
TABLE 306 GCC COUNTRIES: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 265
TABLE 307 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 266
TABLE 308 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 309 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 310 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267
TABLE 311 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 268
TABLE 312 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 268
TABLE 313 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 268
TABLE 314 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 269
TABLE 315 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 269
TABLE 316 SAUDI ARABIA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 269
TABLE 317 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 270
TABLE 318 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 319 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 320 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 271
TABLE 321 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 272
TABLE 322 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2023–2030 (USD MILLION) 272
TABLE 323 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 272
TABLE 324 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2023–2030 (USD MILLION) 273
TABLE 325 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 273
TABLE 326 UAE: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 273
TABLE 327 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 274
TABLE 328 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 274
TABLE 329 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 330 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 275
TABLE 331 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 276
TABLE 332 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 276
TABLE 333 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 276
TABLE 334 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 277
TABLE 335 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 277
TABLE 336 REST OF GCC: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 277
TABLE 337 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 278
TABLE 338 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS,
BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 339 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 340 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 279
TABLE 341 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 280
TABLE 342 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY REVENUE MODEL, 2023–2030 (USD MILLION) 280
TABLE 343 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 280
TABLE 344 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY END USER, 2023–2030 (USD MILLION) 281
TABLE 345 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 281
TABLE 346 SOUTH AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET,
BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 281
TABLE 347 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 282
TABLE 348 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 349 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 350 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 283
TABLE 351 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 284
TABLE 352 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION) 284
TABLE 353 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2030 (USD MILLION) 284
TABLE 354 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030 (USD MILLION) 285
TABLE 355 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PAYER, 2023–2030 (USD MILLION) 285
TABLE 356 REST OF MIDDLE EAST & AFRICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY HEALTHCARE PROVIDER, 2023–2030 (USD MILLION) 285
TABLE 357 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS,
JANUARY 2022–JULY 2025 286
TABLE 358 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEGREE OF COMPETITION 290
TABLE 359 REGIONAL FOOTPRINT 295
TABLE 360 COMPONENT FOOTPRINT 296
TABLE 361 END USER FOOTPRINT 297
TABLE 362 APPLICATION FOOTPRINT 298
TABLE 363 REAL WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 301
TABLE 364 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 301
TABLE 365 REAL WORLD EVIDENCE SOLUTIONS MARKET: PRODUCT LAUNCHES/ENHANCEMENTS, JANUARY 2022–JULY 2025 303
TABLE 366 REAL WORLD EVIDENCE SOLUTIONS MARKET: DEALS, JANUARY 2022–JULY 2025 304
TABLE 367 REAL WORLD EVIDENCE SOLUTIONS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–JULY 2025 305
TABLE 368 IQVIA: COMPANY OVERVIEW 306
TABLE 369 IQVIA: PRODUCTS OFFERED 307
TABLE 370 IQVIA: DEALS, JANUARY 2022–JULY 2025 308
TABLE 371 MERATIVE: COMPANY OVERVIEW 310
TABLE 372 MERATIVE: PRODUCTS OFFERED 310
TABLE 373 MERATIVE: DEALS, JANUARY 2022–JULY 2025 311
TABLE 374 MERATIVE: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 311
TABLE 375 OPTUM, INC.: COMPANY OVERVIEW 313
TABLE 376 OPTUM, INC.: PRODUCTS OFFERED 314
TABLE 377 OPTUM, INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 315
TABLE 378 OPTUM, INC. DEALS, JANUARY 2022–JULY 2025 315
TABLE 379 ICON PLC: COMPANY OVERVIEW 317
TABLE 380 ICON PLC: PRODUCTS OFFERED 318
TABLE 381 ICON PLC: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 319
TABLE 382 ICON PLC: DEALS, JANUARY 2022–JULY 2025 319
TABLE 383 SYNEOS HEALTH: COMPANY OVERVIEW 321
TABLE 384 SYNEOS HEALTH: PRODUCTS OFFERED 321
TABLE 385 SYNEOS HEALTH: DEALS, JANUARY 2022–JULY 2025 322
TABLE 386 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW 324
TABLE 387 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCTS OFFERED 324
TABLE 388 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 325
TABLE 389 PAREXEL INTERNATIONAL (MA) CORPORATION: DEALS, JANUARY 2022–JULY 2025 325
TABLE 390 FLATIRON HEALTH: COMPANY OVERVIEW 327
TABLE 391 FLATIRON HEALTH: PRODUCTS OFFERED 327
TABLE 392 FLATIRON HEALTH: PRODUCT LAUNCHES/DEVELOPMENTS,
JANUARY 2022–JULY 2025 328
TABLE 393 FLATIRON HEALTH: DEALS, JANUARY 2022–JULY 2025 328
TABLE 394 FORTREA: COMPANY OVERVIEW 330
TABLE 395 FORTREA: PRODUCTS OFFERED 331
TABLE 396 FORTREA: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 332
TABLE 397 FORTREA: DEALS, JANUARY 2022–JULY 2025 332
TABLE 398 ORACLE: COMPANY OVERVIEW 333
TABLE 399 ORACLE: PRODUCTS OFFERED 334
TABLE 400 ORACLE: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 335
TABLE 401 ORACLE: DEALS, JANUARY 2022–JULY 2025 335
TABLE 402 ELEVANCE HEALTH: COMPANY OVERVIEW 337
TABLE 403 ELEVANCE HEALTH: PRODUCTS OFFERED 338
TABLE 404 SAS INSTITUTE INC.: COMPANY OVERVIEW 339
TABLE 405 SAS INSTITUTE INC.: PRODUCTS OFFERED 339
TABLE 406 SAS INSTITUTE INC.: PRODUCT LAUNCHES/DEVELOPMENTS,
JANUARY 2022–JULY 2025 340
TABLE 407 AETION, INC.: COMPANY OVERVIEW 341
TABLE 408 AETION, INC.: PRODUCTS OFFERED 341
TABLE 409 AETION, INC.: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 342
TABLE 410 AETION, INC.: DEALS, JANUARY 2022–JULY 2025 342
TABLE 411 TRINETX, LLC: COMPANY OVERVIEW 344
TABLE 412 TRINETX, LLC: PRODUCTS OFFERED 344
TABLE 413 TRINETX, LLC: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 345
TABLE 414 TRINETX, LLC: DEALS, JANUARY 2022–JULY 2025 345
TABLE 415 TRINITY: COMPANY OVERVIEW 347
TABLE 416 TRINITY: PRODUCTS OFFERED 347
TABLE 417 TRINITY: DEALS, JANUARY 2022–JULY 2025 348
TABLE 418 MEDIDATA: COMPANY OVERVIEW 349
TABLE 419 MEDIDATA: PRODUCTS OFFERED 349
TABLE 420 MEDIDATA: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 350
TABLE 421 MEDIDATA: DEALS, JANUARY 2022–JULY 2025 350
TABLE 422 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY OVERVIEW 352
TABLE 423 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: PRODUCTS OFFERED 353
TABLE 424 CEGEDIM HEALTH DATA: COMPANY OVERVIEW 354
TABLE 425 CEGEDIM HEALTH DATA: PRODUCTS OFFERED 355
TABLE 426 CEGEDIM HEALTH DATA: PRODUCT LAUNCHES/DEVELOPMENTS,
JANUARY 2022–JULY 2025 355
TABLE 427 CEGEDIM HEALTH DATA: DEALS, JANUARY 2022–JULY 2025 355
TABLE 428 VERANTOS: COMPANY OVERVIEW 356
TABLE 429 VERANTOS: PRODUCTS OFFERED 356
TABLE 430 VERANTOS: PRODUCT LAUNCHES/DEVELOPMENTS, JANUARY 2022–JULY 2025 357
TABLE 431 VERANTOS: DEALS, JANUARY 2022–JULY 2025 358
TABLE 432 MEDPACE: COMPANY OVERVIEW 359
TABLE 433 MEDPACE: PRODUCTS OFFERED 360
TABLE 434 TATA CONSULTANCY SERVICES LIMITED: COMPANY OVERVIEW 361
TABLE 435 TATA CONSULTANCY SERVICES LIMITED: PRODUCTS OFFERED 362
TABLE 436 TATA CONSULTANCY SERVICES LIMITED: DEALS, JANUARY 2022–JULY 2025 363
TABLE 437 HEALTHVERITY, INC.: COMPANY OVERVIEW 364
TABLE 438 OM1: COMPANY OVERVIEW 364
TABLE 439 OPEN HEALTH: COMPANY OVERVIEW 365
TABLE 440 TEMPUS: COMPANY OVERVIEW 366
TABLE 441 QUANTZIG: COMPANY OVERVIEW 366
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 40
FIGURE 2 PRIMARY SOURCES 43
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 45
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 46
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 47
FIGURE 6 BOTTOM-UP APPROACH 48
FIGURE 7 TOP-DOWN APPROACH 48
FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS, 2024–2030 49
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 50
FIGURE 10 DATA TRIANGULATION METHODOLOGY 51
FIGURE 11 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT,
2025 VS. 2030 (USD MILLION) 54
FIGURE 12 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DATA SETS, BY TYPE,
2025 VS. 2030 (USD MILLION) 55
FIGURE 13 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS,
BY TYPE, 2025 VS. 2030 (USD MILLION) 55
FIGURE 14 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 56
FIGURE 15 REAL WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION) 57
FIGURE 16 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL,
2025 VS. 2030 (USD MILLION) 57
FIGURE 17 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE,
2025 VS. 2030 (USD MILLION) 58
FIGURE 18 REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 58
FIGURE 19 REAL WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 59
FIGURE 20 RISING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 60
FIGURE 21 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES SEGMENT AND
CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024 61
FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 62
FIGURE 23 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 62
FIGURE 24 EMERGING ECONOMIES TO REGISTER SIGNIFICANT GROWTH
DURING FORECAST PERIOD 63
FIGURE 25 REAL WORLD EVIDENCE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 26 NUMBER OF CLINICAL TRIALS ACROSS REGIONS, 2022–2024 68
FIGURE 27 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 75
FIGURE 28 RWE ANALYTICS APPROACH: INTERNAL VS. OUTSOURCED 76
FIGURE 29 ECOSYSTEM ANALYSIS 80
FIGURE 30 REAL WORLD EVIDENCE SOLUTIONS MARKET: VALUE CHAIN ANALYSIS 82
FIGURE 31 REVENUE SHIFT IN REAL WORLD EVIDENCE SOLUTIONS MARKET 84
FIGURE 32 PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 33 JURISDICTION AND TOP APPLICANT ANALYSIS 98
FIGURE 34 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS),
JANUARY 2015 TO JULY 2025 99
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY APPLICATIONS 102
FIGURE 36 KEY BUYING CRITERIA FOR KEY APPLICATIONS 103
FIGURE 37 INVESTMENT & FUNDING SCENARIO 108
FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING REAL WORLD EVIDENCE SOLUTIONS ACROSS INDUSTRIES 109
FIGURE 39 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT MARKET ECOSYSTEM 111
FIGURE 40 NORTH AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT 165
FIGURE 41 ASIA PACIFIC: REAL WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT 210
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 (USD MILLION) 289
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 290
FIGURE 44 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 293
FIGURE 45 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY FOOTPRINT 294
FIGURE 46 REAL WORLD EVIDENCE SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300
FIGURE 47 BRAND/PRODUCT COMPARISON 302
FIGURE 48 EV/EBITDA OF KEY VENDORS 302
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF REAL WORLD EVIDENCE SOLUTIONS, 2024 303
FIGURE 50 IQVIA: COMPANY SNAPSHOT (2024) 307
FIGURE 51 OPTUM, INC.: COMPANY SNAPSHOT (2024) 314
FIGURE 52 ICON PLC: COMPANY SNAPSHOT (2024) 318
FIGURE 53 FORTREA: COMPANY SNAPSHOT (2024) 331
FIGURE 54 ORACLE: COMPANY SNAPSHOT (2024) 334
FIGURE 55 ELEVANCE HEALTH: COMPANY SNAPSHOT (2024) 337
FIGURE 56 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2024) 353
FIGURE 57 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2024) 354
FIGURE 58 MEDPACE: COMPANY SNAPSHOT (2024) 359
FIGURE 59 TATA CONSULTANCY SERVICES LIMITED.: COMPANY SNAPSHOT (2024) 362
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11